

VISEN Pharmaceuticals Announces the Offer Price and Allotment Results of the Global Offering

March 21st, 2025, Hong Kong, China – VISEN Pharmaceuticals (Stock Code: 2561.HK) an innovative biopharmaceutical company focused on endocrine diseases, today announces the allotment results of the global offering (the "Global Offering"). The Offer Price has been determined at HK\$68.8 per Offer Share.

The listing of VISEN Pharmaceuticals in Hong Kong stock market has attracted significant attention from Hong Kong local and international investors. It also represents a great milestone of the Company along its journey in the capital market.

At the listing ceremony, Mr. Pony LU, Executive Director and CEO of VISEN Pharmaceuticals, expressed his heartfelt gratitude to all investors, partners, and employees.

"VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on endocrine-related therapeutic areas. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Our slogan 'Innovation Brings Light to Life' is more than a solemn commitment. VISEN will collaborate with industry partners to drive high-quality advancement in both our enterprise and pharmaceutical innovation ecosystem in China."

As a global unicorn company, VISEN Pharmaceuticals has previously established strategic collaborations with industry-leading enterprises such as Shanghai Pharmaceuticals Holding (a subsidiary of SPH Group), WuXi Biologics, United Family Healthcare and MedSci, paving the way for the commercialization of its core product. Furthermore, VISEN Pharmaceuticals has garnered support from top-tier investors including HongShan China, OrbiMed, Sherpa, Cormorant, HBM Healthcare Investments, Pivotal bioVenture, Logos Capital, and CDG Capital. For its IPO, the Company has secured five cornerstone investors: Anhui Anke Biotechnology (Group), Suzhou Industrial Park Industrial Investment Fund, Vivo Capital, WuXi Biologics, and Reynold Lemkins.

The successful listing represents a significant milestone in the company's journey forward, inaugurating a new chapter for the Company. By entering the international capital markets and leveraging this listing as a strategic catalyst, the Company will accelerate the regulatory approval and commercialization processes for multiple pipeline products focusing on areas including growth hormone deficiency, hypoparathyroidism, achondroplasia, and other potential endocrine diseases. Through its dual-engine model by integrating in-house R&D with Exclusive Licence, VISEN aims to drive quality innovation in endocrinology and deliver enhanced therapeutic options for patients with endocrine diseases.

VISEN Pharmaceuticals will collaborate with partners in each sectors to promote multidimensional initiatives such as disease awareness campaigns, patient education programs, and holistic disease management systems, helping more patients gain access to scientific and precise treatments at an early stage. These efforts align with the corporate vision of “Every endocrine patient can live life to the fullest with innovative therapies and compassionate care”.

About VISEN Pharmaceuticals

VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients' need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases. VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market - have set up HQs in Suzhou, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier.